Northern Trust Corp Arcus Biosciences, Inc. Transaction History

Northern Trust Corp

  • $658 Billion
  • Q1 2025

A detailed history of Northern Trust Corp transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 570,042 shares of RCUS stock, worth $4.99 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
570,042
Previous 532,099 7.13%
Holding current value
$4.99 Million
Previous $7.92 Million 43.52%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 13, 2025
BUY
$7.85 - $15.24 $297,852 - $578,251
37,943 Added 7.13%
570,042 $4.47 Million
Q4 2024

Feb 14, 2025
BUY
$14.28 - $18.44 $316,744 - $409,017
22,181 Added 4.35%
532,099 $7.92 Million
Q3 2024

Nov 13, 2024
BUY
$13.69 - $18.01 $116,159 - $152,814
8,485 Added 1.69%
509,918 $7.8 Million
Q2 2024

Aug 14, 2024
SELL
$14.59 - $18.48 $176,028 - $222,961
-12,065 Reduced 2.35%
501,433 $7.64 Million
Q1 2024

May 14, 2024
SELL
$14.83 - $20.18 $165,962 - $225,834
-11,191 Reduced 2.13%
513,498 $9.69 Million
Q4 2023

Feb 13, 2024
BUY
$13.43 - $19.63 $96,763 - $141,434
7,205 Added 1.39%
524,689 $10 Million
Q3 2023

Nov 13, 2023
BUY
$17.62 - $23.54 $179,177 - $239,378
10,169 Added 2.0%
517,484 $9.29 Million
Q2 2023

Aug 11, 2023
SELL
$16.97 - $22.03 $401,510 - $521,229
-23,660 Reduced 4.46%
507,315 $10.3 Million
Q1 2023

May 15, 2023
SELL
$15.96 - $23.15 $2.87 Million - $4.16 Million
-179,647 Reduced 25.28%
530,975 $9.68 Million
Q4 2022

Feb 13, 2023
BUY
$19.7 - $35.71 $346,995 - $628,995
17,614 Added 2.54%
710,622 $14.7 Million
Q3 2022

Nov 14, 2022
BUY
$23.23 - $30.07 $266,169 - $344,542
11,458 Added 1.68%
693,008 $18.1 Million
Q2 2022

Aug 12, 2022
BUY
$17.23 - $37.73 $1.4 Million - $3.06 Million
81,142 Added 13.51%
681,550 $17.3 Million
Q1 2022

May 13, 2022
SELL
$28.92 - $41.83 $690,089 - $998,147
-23,862 Reduced 3.82%
600,408 $18.9 Million
Q4 2021

Feb 08, 2022
SELL
$31.38 - $48.47 $500,887 - $773,678
-15,962 Reduced 2.49%
624,270 $25.3 Million
Q3 2021

Nov 15, 2021
SELL
$26.93 - $37.68 $752,666 - $1.05 Million
-27,949 Reduced 4.18%
640,232 $22.3 Million
Q2 2021

Aug 13, 2021
BUY
$22.75 - $35.77 $3.81 Million - $5.99 Million
167,335 Added 33.41%
668,181 $18.3 Million
Q1 2021

May 12, 2021
SELL
$26.16 - $41.39 $908,249 - $1.44 Million
-34,719 Reduced 6.48%
500,846 $14.1 Million
Q4 2020

Feb 11, 2021
SELL
$17.0 - $32.36 $287,011 - $546,333
-16,883 Reduced 3.06%
535,565 $13.9 Million
Q3 2020

Nov 16, 2020
BUY
$17.14 - $25.47 $1.12 Million - $1.66 Million
65,365 Added 13.42%
552,448 $9.47 Million
Q2 2020

Aug 14, 2020
BUY
$13.97 - $36.56 $1.19 Million - $3.12 Million
85,252 Added 21.22%
487,083 $12.1 Million
Q1 2020

May 14, 2020
BUY
$8.78 - $19.28 $131,383 - $288,505
14,964 Added 3.87%
401,831 $5.58 Million
Q4 2019

Feb 14, 2020
BUY
$7.33 - $10.79 $168,919 - $248,655
23,045 Added 6.33%
386,867 $3.91 Million
Q3 2019

Nov 13, 2019
BUY
$6.44 - $10.18 $203,285 - $321,341
31,566 Added 9.5%
363,822 $3.31 Million
Q2 2019

Aug 13, 2019
BUY
$7.29 - $13.38 $136,293 - $250,152
18,696 Added 5.96%
332,256 $2.64 Million
Q1 2019

May 13, 2019
BUY
$8.95 - $12.49 $93,536 - $130,532
10,451 Added 3.45%
313,560 $3.92 Million
Q4 2018

Feb 12, 2019
BUY
$9.74 - $14.5 $1.94 Million - $2.89 Million
199,175 Added 191.64%
303,109 $3.27 Million
Q3 2018

Nov 14, 2018
BUY
$10.88 - $14.95 $443,196 - $608,988
40,735 Added 64.46%
103,934 $1.45 Million
Q2 2018

Aug 14, 2018
BUY
$12.24 - $17.05 $773,555 - $1.08 Million
63,199 New
63,199 $774,000

Others Institutions Holding RCUS

# of Institutions
200
Shares Held
63.1M
Call Options Held
116K
Put Options Held
116K
View Full List

About Arcus Biosciences, Inc.

RCUS Quotes by TradingView
  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $631M
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email